SCHEMBL1611218

SCHEMBL1611218

N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]cc(O)c23)cn1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 13/20 0.68
JAK1 P23458 11/20 0.68
JAK3 P52333 4/20 0.68
ABL1 P00519 3/20 0.68
TYK2 P29597 3/20 0.68
DAPK3 O43293 2/20 0.68
PAK4 O96013 2/20 0.68
RET P07949 2/20 0.68
LTK P29376 2/20 0.68
CSNK1A1 P48729 2/20 0.68
CLK2 P49760 2/20 0.68
TNK2 Q07912 2/20 0.68
ROCK1 Q13464 2/20 0.68
DYRK1A Q13627 2/20 0.68
IKBKE Q14164 2/20 0.68
NTRK3 Q16288 2/20 0.68
NTRK2 Q16620 2/20 0.68
LRRK2 Q5S007 2/20 0.68
TAOK1 Q7L7X3 2/20 0.68
CAMK1D Q8IU85 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1612173 0.90 JAK2 (0.55) JAK2JAK1JAK3ABL1TYK2
SCHEMBL1612841 0.88 JAK2 (0.53) JAK2JAK1JAK3ABL1TYK2
SCHEMBL1612013 0.87 JAK2 (0.55) JAK2JAK1JAK3ABL1TYK2
SCHEMBL1612676 0.85 JAK2 (0.65) JAK2JAK1JAK3ABL1TYK2
SCHEMBL1612738 0.84 JAK2 (0.47) JAK2JAK1JAK3ABL1TYK2
SCHEMBL1611857 0.83 JAK2 (0.49) JAK2JAK1JAK3ABL1TYK2
SCHEMBL1612701 0.81 JAK2 (0.47) JAK2JAK1JAK3ABL1TYK2
SCHEMBL1611522 0.81 JAK2 (0.70) JAK2JAK1JAK3ABL1TYK2
Ruxolitinib SCHEMBL101279 0.81 JAK2 (1.00) JAK2JAK1JAK3ABL1TYK2
Ruxolitinib SCHEMBL171319 0.81 JAK2 (1.00) JAK2JAK1JAK3ABL1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105541847-B The hydroxy derivatives, ketone group derivative and glucuronide of 3- (4- (7H- pyrrolo- [2,3-d] pyrimidine-4-yl) -1H- pyrazol-1-yl) -3- cyclopenta propionitrile 因西特控股公司 2019-08-16 CN claimed
CN-105541847-A Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile INCYTE CORP 2016-05-04 CN claimed
US-20140378400-A1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE INCYTE CORPORATION 2014-12-25 US claimed
EP-2486041-B1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE INCYTE CORP (US) 2013-08-14 EP claimed
US-8486902-B2 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile INCYTE CORPORATION (US) 2013-07-16 US claimed
EP-2486041-A1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE Incyte Corporation (US) 2012-08-15 EP claimed
CN-102596960-A Hydroxy, keto, and glucuronide derivatives of 3- (4- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile INCYTE CORP 2012-07-18 CN claimed
US-20110086810-A1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE INCYTE CORPORATION (US) 2011-04-14 US claimed
WO-2011044481-A1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE INCYTE CORPORATION (US) 2011-04-14 WO claimed
CN-105541847-B The hydroxy derivatives, ketone group derivative and glucuronide of 3- (4- (7H- pyrrolo- [2,3-d] pyrimidine-4-yl) -1H- pyrazol-1-yl) -3- cyclopenta propionitrile 因西特控股公司 2019-08-16 CN disclosed
US-9512161-B2 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile INCYTE CORPORATION (US) 2016-12-06 US disclosed
US-9512161-B2 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile INCYTE CORPORATION (US) 2016-12-06 US disclosed
US-9512161-B2 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile INCYTE CORPORATION (US) 2016-12-06 US disclosed
CN-105541847-A Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile INCYTE CORP 2016-05-04 CN disclosed
US-8486902-B2 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile INCYTE CORPORATION (US) 2013-07-16 US disclosed
CN-102596960-A Hydroxy, keto, and glucuronide derivatives of 3- (4- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile INCYTE CORP 2012-07-18 CN disclosed
US-20110086810-A1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE INCYTE CORPORATION (US) 2011-04-14 US disclosed
US-20110086810-A1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE INCYTE CORPORATION (US) 2011-04-14 US disclosed
US-20110086810-A1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE INCYTE CORPORATION (US) 2011-04-14 US disclosed
WO-2011044481-A1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE INCYTE CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086810-A1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE UGT1A4, UGT1A3, UGT1A1 JAK2 3506/4885JAK1 2614/4885JAK3 2001/4885
US-20140378400-A1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE UGT1A4, UGT1A3, UGT1A1 JAK2 3506/4885JAK1 2614/4885JAK3 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.